Has Alfred Hutcheson received payments from drug or device companies?

Yes. Drug and device makers reported $4,919 in general payments to Alfred Hutcheson across 254 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alfred Hutcheson did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alfred Hutcheson come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alfred Hutcheson

Cardiovascular Disease · Madison, MSNPI 1821002833

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 254 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,714 and has fallen 92.5% since, to $128 in 2024.

$4,919in general payments, 2019–2025

Across 254 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$801
Amgen$731
Boehringer Ingelheim$599
AstraZeneca$477
Novartis$388
Merck$314
plus $2K from 12 others

What the payments were for

Food & beverage$4,897100%
Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	61	$801
Amgen	41	$731
Boehringer Ingelheim	27	$599
AstraZeneca	20	$477
Novartis	25	$388
Merck	13	$314
Boston Scientific	2	$233
Chiesi USA, Inc.	2	$222
E.r. Squibb & Sons, L.L.C.	13	$187
Kowa Pharmaceuticals America, Inc.	11	$169
Esperion Therapeutics, Inc.	8	$160
Sanofi-aventis U.S. LLC	7	$129
Penumbra, Inc.	1	$111
Astellas Pharma US Inc	5	$100
Pfizer	6	$99
Regeneron Healthcare Solutions, Inc.	5	$93
Amarin Pharma, Inc.	5	$83
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	2	$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,919 in reported general payments places this provider in the 55th percentile of 144 cardiovascular disease providers in Mississippi.

See all cardiovascular disease providers in Mississippi →

Other cardiovascular disease in Madison

Dharmesh PatelSouthaven$1.5M
Barry BertoletTupelo$469K
Donny StokesJackson$207K
Mahmoud ZayedPascagoula$103K
James BenslerJackson$64K
Michael HallJackson$54K
Hugo QuintanaPascagoula$48K
Ediz TasanPascagoula$42K
Lawrence LeaderHattiesburg$40K
Matthew HannKeesler Afb$40K

See the full list for Mississippi →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →